Wyeth’s International OTC Growth Offsets Drop In U.S. Robitussin Sales
This article was originally published in The Tan Sheet
Executive Summary
Sales of Wyeth's OTC products increased 10.4 percent worldwide in its fiscal 2008 first quarter despite a 14.2 percent drop in sales of its Robitussin cough/cold products, the firm says
You may also be interested in...
Wyeth Replaces Dosing Measure For Pediatric Dimetapp, Robitussin Products
Wyeth Consumer Healthcare is voluntarily recalling and replacing Children's Dimetapp Cold & Chest Congestion and multiple products in its Robitussin line because the products' dosing cups are not marked with half-teaspoon units, the recommended dose for children ages 2 to 6, the firm said Oct. 29
Infant Cold Products Pulled; Waxman Looks For More OTC Risks
Manufacturers of OTC cough/cold medicines for children under 2 years old are voluntarily withdrawing the products from the market due to potential misuse, not from product safety concerns, the Consumer Healthcare Products Association said Oct. 11
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.